$19.56
-0.42 (-2.10%)
Open$19.77
Previous Close$19.98
Day High$20.34
Day Low$19.26
52W High$26.00
52W Low$6.50
Volume—
Avg Volume727.9K
Market Cap1.03B
P/E Ratio1.64
EPS$-43.00
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+77.6% upside
Current
$19.56
$19.56
Target
$34.74
$34.74
$25.90
$34.74 avg
$38.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 29.07M | 27.10M | 30.53M |
| Net Income | 5.84M | 4.59M | 6.02M |
| Profit Margin | 20.1% | 16.9% | 19.7% |
| EBITDA | 8.15M | 7.65M | 7.71M |
| Free Cash Flow | 6.21M | 7.09M | 6.33M |
| Rev Growth | +18.1% | +12.4% | +4.7% |
| Debt/Equity | 0.64 | 0.68 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |